Insider Trading
Taysha Gene Therapies Insider Sold Shares Worth $892,000, According to a Recent SEC Filing
Sukumar Nagendran, Director, President, and Head of R&D, on April 10, 2026, sold 200,000 shares in Taysha Gene Therapies (TSHA) for $892,000. Following the Form 4 filing with the SEC, Nagendran has control over a total of 1,136,410 common shares of the company, with 1,136,410 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1806310/000166512426000011/xslF345X05/form4-04132026_080454.xml
$TSHA
